Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 27 Recurrence 3 Hematologic Neoplasms 2 Waldenstrom Macroglobulinemia 1 Neoplasm, Residual 1 Myasthenia Gravis 1 Cytokine Release Syndrome 1

Interventions

Cyclophosphamide 22 blinatumomab 18 Cytarabine 15 fludarabine 13 Azacitidine 12 venetoclax 10 fludarabine phosphate 10 Rituximab 8 Lenalidomide 7 Dexamethasone 7 Methotrexate 6 Daunorubicin 6 Mercaptopurine 5 daratumumab 4 Whole-Body Irradiation 4 Vincristine 4 Melphalan 4 Idarubicin 4 Etoposide 4 Busulfan 4 pembrolizumab 3 obinutuzumab 3 Radiotherapy 3 Maintenance 3 Immunotherapy, Adoptive 3 Imatinib Mesylate 3 Granulocyte Colony-Stimulating Factor 3 Drug Therapy 3 Cladribine 3 Asparaginase 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasm, Residual × talquetamab × Clear all

NCT06993675 2026-05-13

ROTATE

Yale University

Phase 2 Recruiting

Multiple Myeloma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡